Shares of Palatin Technologies Inc. (PTN) were up over 57% in extended trading on Tuesday, following positive results from its two phase III trials of Bremelanotide in premenopausal women with hypoactive sexual desire disorder.
from RTT - Biotech http://ift.tt/2fd2UPv
via IFTTT
No comments:
Post a Comment